You are here: Industry Insights > Roche

News List

FDA greenlights Roche and AbbVie's Venclexta for chronic lymphocytic leukaemia pharmafile
May 17, 2019
Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in combination with Gazyva (obinutuzumab) for ...
Roche's Ocrevus continues winning streak as NICE flip-flops on initial rejection fiercepharma
May 12, 2019
Roche’s multiple sclerosis superstar Ocrevus has run into few obstacles on its path to nearly $1 billion in global sales this year.
NICE backs use of Ocrevus in primary progressive multiple sclerosis after Roche reaches pricing deal with NHS firstwordpharma
May 10, 2019
The National Institute for Health and Care Excellence issued final draft guidance Thursday recommending NHS reimbursement of Roche's Ocrevus (ocrelizumab) for treating primary progressive multiple sclerosis (PPMS) in adults.
Roche launches HER2 biomarker test for breast and gastric cancer pharmatimes
May 09, 2019
Roche has launched a new assay that can detect the HER2 biomarker in breast and gastric cancer in the UK.
Roche's Tecentriq-Avastin lung cancer combo gets a lift from England's cost watchdogs biospectrumasia
May 06, 2019
Roche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lung cancer.
Roche reports a strong start in 2019 and raises the outlook for the full-year worldpharmanews
April 23, 2019
Roche reports a strong start in 2019 and raises the outlook for the full-year...
Roche throws in the towel on Tecentriq bladder, myeloma trials fiercepharma
April 21, 2019
Roche’s Tecentriq has scored some important victories lately, including a pair of first-in-class approvals. But in other types of cancer, the Swiss drugmaker has decided to pull the plug.
Roche's drugs, new and old, team up for major sales—sans price hikes fiercepharma
April 18, 2019
Last July, Roche put a halt on drug price increases in the U.S. But that didn't stop five of its products from topping analysts' sales estimates by double digits to start the year.
I-Mab Biopharma collaborates with Roche for combination therapy biospectrumasia
April 11, 2019
I-Mab Biopharma (I-Mab), a clinical stage biopharmaceutical company exclusively focused on the development of ……
Herceptin has been Excellent over the Two Decades PharmaSources/Miling
April 10, 2019
The subcutaneous injection: Herceptin Hylecta of the star drug Herceptin under Roche has recently been approved by FDA for...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page